ArticleEndocrine connections2026
Impact of GAD-65 antibody detection on antihyperglycemic therapy in T2D.
Article in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Guidelines recommend that latent autoimmune diabetes in adults be managed similarly to type 1 diabetes, emphasizing early insulin initiation, while other guidance suggests incorporating non-insulin antihyperglycemic therapies based on comorbidities and C-peptide levels. The objective of this study was to explore whether glutamic acid decarboxylase-65 autoantibody detection in individuals diagnosed with type 2 diabetes impacts antihyperglycemic treatment. This retrospective, observational cohort study at an academic integrated delivery network in Northeast Ohio utilized electronic medical records. Individuals previously diagnosed with type 2 diabetes who tested positive for glutamic acid decarboxylase-65 autoantibodies between September 1, 2021, and September 1, 2023, were included. The primary outcome compared the median number of non-insulin antihyperglycemic medication classes at the time of autoantibody detection and after 12 months. Participants had a mean age of 57.2 ± 13.7 years, 73.3% were white, with a median body mass index of 26.2 kg/m2, and 82.1% had an estimated glomerular filtration rate greater than 60 mL/min/1.73 m2. A median of 1 (0-2) non-insulin antihyperglycemic medication class was present at detection and 1 (0-1.5) post-detection (P < 0.0001). Significantly fewer individuals were prescribed metformin, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, sulfonylureas, and thiazolidinediones, whereas significantly more individuals were prescribed bolus insulin after detection. Although most individuals had a baseline C-peptide value within 12 months prior to detection, significantly fewer C-peptide assessments occurred during the subsequent 12-month follow-up period. In individuals with type 2 diabetes, glutamic acid decarboxylase-65 autoantibody detection was associated with significantly fewer prescribed non-insulin antihyperglycemics and significantly more insulin agents 12 months after detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.